Sun Pharma faced a setback as SCD-044, a drug under Phase-2 trial for atopic dermatitis and psoriasis, failed to meet the efficacy endpoint. Despite passing Phase-1 safety evaluation, the molecule did not achieve the required improvement in PASI and EASI scores at week 16. This outcome is significant as it impacts Sun Pharma’s pipeline and […]
Category: Sun Pharmaceuticals
Sun Pharma AR Suffers 20% Drop as Psoriasis Drug Fails Trials
Sun Pharma Advanced Research faces a 20% stock decline following the disappointment of SCD-044, an oral pill aimed at combating inflammatory skin conditions by targeting S1P receptor 1. This receptor is crucial in regulating immune cell movement, and the drug was anticipated to alleviate disease severity by influencing lymphocyte migration out of lymphatic tissues. Previous […]
Sun Pharmaceutical underperforms competitors Wednesday
Sun Pharmaceutical Industries Ltd. (524715) shares experienced a slight decline of 0.14% to 1,665.25 Indian rupees on Wednesday. This decrease occurred amidst an overall positive trading session for the stock market, as indicated by the 0.32% rise in the BSE SENSEX Index to 80,998.25. Sun Pharmaceutical, a key player in the pharmaceutical industry, faced challenges […]
